Quolet develops Soli-Sol technology focused on improving the delivery of Cannabidiol (CBD). The company utilizes novel lipid solid solution formulations to enhance bioavailability and efficacy. This specialized approach targets pharmaceutical and nutraceutical applications requiring optimized CBD absorption.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cannabidiol (CBD) formulations often suffer from poor bioavailability, limiting the amount of active compound that reaches systemic circulation and reducing therapeutic efficacy. This low absorption rate necessitates higher doses, increasing costs and potentially leading to unwanted side effects.
Solution
Quolet Industries utilizes a proprietary lipid solid solution technology to enhance the bioavailability and delivery efficiency of CBD. This approach encapsulates CBD molecules within a biocompatible lipid matrix, improving their solubility and absorption in the gastrointestinal tract. By increasing the amount of CBD that reaches the bloodstream, Quolet's technology enables lower effective doses, reduces product waste, and improves therapeutic outcomes. The resulting formulations can be incorporated into various product formats, including capsules, tablets, and topical creams.
Target Audience
Quolet Industries primarily targets CBD product manufacturers seeking to improve the efficacy and bioavailability of their offerings.
Features
- Lipid solid solution technology for enhanced CBD bioavailability
- Improved solubility and absorption of CBD in the gastrointestinal tract
- Increased systemic delivery of CBD compared to traditional formulations
- Customizable formulations for various product formats